US6645969B1
(en)
|
1991-05-10 |
2003-11-11 |
Aventis Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
|
TW321649B
(fr)
*
|
1994-11-12 |
1997-12-01 |
Zeneca Ltd |
|
GB9424233D0
(en)
*
|
1994-11-30 |
1995-01-18 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508538D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508535D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivative
|
GB9508565D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
GB9508537D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
AU5343096A
(en)
*
|
1995-04-27 |
1996-11-18 |
Zeneca Limited |
Quinazoline derivatives
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
US5760041A
(en)
*
|
1996-02-05 |
1998-06-02 |
American Cyanamid Company |
4-aminoquinazoline EGFR Inhibitors
|
ES2194181T3
(es)
|
1996-02-13 |
2003-11-16 |
Astrazeneca Ab |
Derivados de quinazolina como inhibidores de vegf.
|
GB9603097D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
DK0885198T3
(da)
|
1996-03-05 |
2002-03-25 |
Astrazeneca Ab |
4-Anilinoquinazolinderivater
|
CA2249446C
(fr)
|
1996-04-12 |
2008-06-17 |
Warner-Lambert Company |
Inhibiteurs irreversibles de tyrosine kinases
|
GB9607729D0
(en)
*
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
FR2750862B1
(fr)
*
|
1996-07-12 |
1998-10-16 |
Dupin Jean Pierre |
Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques
|
WO1998002434A1
(fr)
|
1996-07-13 |
1998-01-22 |
Glaxo Group Limited |
Composes heterocycliques condenses en tant qu'inhibiteurs de la proteine tyrosine kinase
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
AU4342997A
(en)
*
|
1996-09-13 |
1998-04-02 |
Sugen, Inc. |
Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
|
US6004967A
(en)
*
|
1996-09-13 |
1999-12-21 |
Sugen, Inc. |
Psoriasis treatment with quinazoline compounds
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
AU733551B2
(en)
|
1996-09-25 |
2001-05-17 |
Astrazeneca Ab |
Qinoline derivatives inhibiting the effect of growth factors such as VEGF
|
AU719392B2
(en)
*
|
1996-10-01 |
2000-05-11 |
Kyowa Hakko Kirin Co., Ltd. |
Nitrogen-containing heterocyclic compounds
|
EP0837063A1
(fr)
*
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
Dérivés de 4-aminoquinazoline
|
US6225318B1
(en)
|
1996-10-17 |
2001-05-01 |
Pfizer Inc |
4-aminoquinazolone derivatives
|
US6002008A
(en)
*
|
1997-04-03 |
1999-12-14 |
American Cyanamid Company |
Substituted 3-cyano quinolines
|
UA73073C2
(uk)
*
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
US5929080A
(en)
*
|
1997-05-06 |
1999-07-27 |
American Cyanamid Company |
Method of treating polycystic kidney disease
|
ZA986732B
(en)
*
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitiors of tyrosine kinases
|
ZA986729B
(en)
*
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitors of tyrosine kinases
|
TW436485B
(en)
*
|
1997-08-01 |
2001-05-28 |
American Cyanamid Co |
Substituted quinazoline derivatives
|
US6251912B1
(en)
|
1997-08-01 |
2001-06-26 |
American Cyanamid Company |
Substituted quinazoline derivatives
|
US6323209B1
(en)
|
1997-11-06 |
2001-11-27 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps
|
GB9800575D0
(en)
*
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
JP4253126B2
(ja)
|
1998-01-29 |
2009-04-08 |
アムジェン インコーポレイテッド |
Ppar−ガンマ調節剤
|
ES2356886T3
(es)
*
|
1998-03-31 |
2011-04-14 |
Kyowa Hakko Kirin Co., Ltd. |
Compuestos heterocíclicos nitrogenados.
|
US6706721B1
(en)
|
1998-04-29 |
2004-03-16 |
Osi Pharmaceuticals, Inc. |
N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
|
JP2002516823A
(ja)
|
1998-05-28 |
2002-06-11 |
パーカー ヒューズ インスティテュート |
脳腫瘍の治療のためのキナゾリン
|
US6800649B1
(en)
|
1998-06-30 |
2004-10-05 |
Parker Hughes Institute |
Method for inhibiting c-jun expression using JAK-3 inhibitors
|
RS50273B
(sr)
|
1998-08-18 |
2009-07-15 |
The Regents Of The Univeristy Of California, |
Antagonisti receptora epidermalnog faktora rasta za lečenje hipersekrecije mukusa u plućima
|
US7354894B2
(en)
|
1998-08-18 |
2008-04-08 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of EGF-R antagonists
|
WO2000010981A1
(fr)
|
1998-08-21 |
2000-03-02 |
Parker Hughes Institute |
Derives de quinazoline
|
EP1510212A1
(fr)
*
|
1998-08-21 |
2005-03-02 |
Parker Hughes Institute |
Utilisation de 4-dérives de quinazoline pour la préparation de produits thérapeutiques
|
US6288082B1
(en)
|
1998-09-29 |
2001-09-11 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
AU2012209038B2
(en)
*
|
1998-09-29 |
2013-09-26 |
Wyeth Holdings Corporation |
Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
|
US6297258B1
(en)
|
1998-09-29 |
2001-10-02 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
DK2253620T3
(da)
*
|
1998-09-29 |
2014-03-31 |
Wyeth Holdings Llc |
Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
|
GB9824579D0
(en)
*
|
1998-11-10 |
1999-01-06 |
Novartis Ag |
Organic compounds
|
TR200102090T2
(tr)
|
1999-01-22 |
2002-01-21 |
Kirin Beer Kabushiki Kaisha |
Kinolin türevleri ve kinazolin türevleri.
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
UA71945C2
(en)
*
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
GB9904103D0
(en)
|
1999-02-24 |
1999-04-14 |
Zeneca Ltd |
Quinoline derivatives
|
US6258820B1
(en)
|
1999-03-19 |
2001-07-10 |
Parker Hughes Institute |
Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
|
GB9910579D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
GB9910580D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
US7041691B1
(en)
|
1999-06-30 |
2006-05-09 |
Amgen Inc. |
Compounds for the modulation of PPARγ activity
|
US6933299B1
(en)
|
1999-07-09 |
2005-08-23 |
Smithkline Beecham Corporation |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
ATE377597T1
(de)
|
1999-07-09 |
2007-11-15 |
Glaxo Group Ltd |
Anilinochinazoline als protein-tyrosin- kinasehemmer
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
JP4870304B2
(ja)
*
|
1999-09-21 |
2012-02-08 |
アストラゼネカ アクチボラグ |
キナゾリン誘導体およびそれらの医薬品としての使用
|
CA2384282A1
(fr)
|
1999-09-21 |
2001-03-29 |
Astrazeneca Ab |
Composes de quinazoline et compositions pharmaceutiques comprenant lesdits composes
|
KR100881105B1
(ko)
|
1999-11-05 |
2009-02-02 |
아스트라제네카 아베 |
Vegf 억제제로서의 퀴나졸린 유도체
|
US7087613B2
(en)
|
1999-11-11 |
2006-08-08 |
Osi Pharmaceuticals, Inc. |
Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
UA75055C2
(uk)
*
|
1999-11-30 |
2006-03-15 |
Пфайзер Продактс Інк. |
Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
|
US6638929B2
(en)
|
1999-12-29 |
2003-10-28 |
Wyeth |
Tricyclic protein kinase inhibitors
|
JP2003520855A
(ja)
|
2000-01-28 |
2003-07-08 |
アストラゼネカ アクチボラグ |
化学的化合物
|
FI20000480A0
(fi)
*
|
2000-03-01 |
2000-03-01 |
Orion Yhtymae Oyj |
Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina
|
US6593324B2
(en)
|
2000-03-01 |
2003-07-15 |
Orion Corporation |
Dervatives of quinoline as alpha-2 antagonists
|
US6521618B2
(en)
|
2000-03-28 |
2003-02-18 |
Wyeth |
3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
|
US6608048B2
(en)
|
2000-03-28 |
2003-08-19 |
Wyeth Holdings |
Tricyclic protein kinase inhibitors
|
GB0007657D0
(en)
*
|
2000-03-29 |
2000-05-17 |
Celltech Therapeutics Ltd |
Chemical compounds
|
US20030152572A1
(en)
*
|
2000-04-06 |
2003-08-14 |
Yoshimi Homma |
Diagnostic and therapeutic agents for rheumatoid arthritis
|
DE60121931T2
(de)
|
2000-04-07 |
2007-03-01 |
Astrazeneca Ab |
Chinazolinverbindungen
|
AU6118001A
(en)
|
2000-05-03 |
2001-11-12 |
Tularik Inc |
Combination therapeutic compositions and methods of use
|
DE10023484A1
(de)
*
|
2000-05-09 |
2001-11-22 |
Schering Ag |
Anthranylamide und deren Verwendung als Arzneimittel
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
HU229624B1
(en)
*
|
2000-06-30 |
2014-03-28 |
Glaxo Group Ltd |
Quinazoline ditosylate salt compounds
|
EP2277877A1
(fr)
|
2000-08-18 |
2011-01-26 |
Millennium Pharmaceuticals, Inc. |
Dérivés de quinazoline en tant qu'inhibiteurs de la kinase
|
PL202812B1
(pl)
|
2000-08-21 |
2009-07-31 |
Astrazeneca Ab |
Pochodna chinazoliny, jej kompozycja famaceutyczna oraz jej zastosowanie
|
DE10042059A1
(de)
*
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
EP1777218B1
(fr)
|
2000-10-20 |
2008-12-31 |
Eisai R&D Management Co., Ltd. |
Procédé pour la préparation des dérivés de 4-phenoxy quinolines
|
WO2002036587A2
(fr)
|
2000-11-01 |
2002-05-10 |
Cor Therapeutics, Inc. |
Composes heterocycliques azotes et procede de fabrication de ces composes et de leurs intermediaires
|
US7067532B2
(en)
|
2000-11-02 |
2006-06-27 |
Astrazeneca |
Substituted quinolines as antitumor agents
|
WO2002036570A1
(fr)
*
|
2000-11-02 |
2002-05-10 |
Astrazeneca Ab |
Quinoleines 4 substitues en position 4 utilisees comme agents antitumoraux
|
GB0104422D0
(en)
*
|
2001-02-22 |
2001-04-11 |
Glaxo Group Ltd |
Quinoline derivative
|
GB0110797D0
(en)
*
|
2001-05-02 |
2001-06-27 |
Celltech R&D Ltd |
Chemical compounds
|
US20060004437A1
(en)
|
2001-08-29 |
2006-01-05 |
Swaminathan Jayaraman |
Structurally variable stents
|
US7495104B2
(en)
|
2001-10-17 |
2009-02-24 |
Kirin Beer Kabushiki Kaisha |
Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors
|
DE60231230D1
(de)
*
|
2001-11-03 |
2009-04-02 |
Astrazeneca Ab |
Quinazolin derivate als antitumor-mittel
|
GB0126433D0
(en)
*
|
2001-11-03 |
2002-01-02 |
Astrazeneca Ab |
Compounds
|
CN1608062A
(zh)
*
|
2001-12-12 |
2005-04-20 |
辉瑞产品公司 |
E-2-甲氧基-n-(3-{4-[3-甲基-4-(6-甲基-吡啶-3-基氧基) -苯氨基]-喹唑啉-6基}-烯丙基)-乙酰胺的盐,其制备和抗癌用途
|
ES2333702T3
(es)
|
2001-12-24 |
2010-02-26 |
Astrazeneca Ab |
Derivados de quinazolina sustituidos que actuan como unhibidores de cinasas aurora.
|
TW200406390A
(en)
|
2002-01-17 |
2004-05-01 |
Neurogen Corp |
Substituted quinazolin-4-ylamine analogues
|
WO2003066602A1
(fr)
|
2002-02-06 |
2003-08-14 |
Ube Industries, Ltd. |
Procede relatif a l'elaboration d'un compose 4-aminoquinazoline
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
GB0215823D0
(en)
|
2002-07-09 |
2002-08-14 |
Astrazeneca Ab |
Quinazoline derivatives
|
US7504408B2
(en)
|
2002-07-09 |
2009-03-17 |
Astrazeneca Ab |
Quinzoline derivatives for use in the treatment of cancer
|
EP2280003B1
(fr)
|
2002-07-15 |
2014-04-02 |
Symphony Evolution, Inc. |
Procédé pour la préparation de modulateurs de kinases de type récepteur
|
US7615565B2
(en)
|
2002-07-31 |
2009-11-10 |
Bayer Schering Pharma Aktiengesellschaft |
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
|
EP1542989B1
(fr)
|
2002-07-31 |
2007-04-18 |
Critical Outcome Technologies, Inc. |
Inhibiteurs de proteine tyrosine kinase
|
ATE380810T1
(de)
|
2002-10-09 |
2007-12-15 |
Critical Outcome Technologies |
Protein-tyrosine-kinase-inhibitoren
|
GB0225579D0
(en)
|
2002-11-02 |
2002-12-11 |
Astrazeneca Ab |
Chemical compounds
|
SI1562955T1
(sl)
|
2002-11-04 |
2008-06-30 |
Astrazeneca Ab |
Derivati kinazolina kot inhibitorji Src-triozin kinaze
|
US7488823B2
(en)
|
2003-11-10 |
2009-02-10 |
Array Biopharma, Inc. |
Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
|
DK1625121T3
(da)
|
2002-12-20 |
2010-05-10 |
Pfizer Prod Inc |
Pyrimidinderivater til behandling af abnorm cellevækst
|
SI1578755T1
(sl)
|
2002-12-24 |
2007-12-31 |
Astrazeneca Ab |
Fosfonooksi kinazolinski derivati in njihova farmacevtska uporaba
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
JP2007501854A
(ja)
|
2003-05-27 |
2007-02-01 |
ファイザー・プロダクツ・インク |
受容体型チロシンキナーゼ阻害薬としてのキナゾリン類およびピリド[3,4−d]ピリミジン類
|
JO2785B1
(en)
*
|
2003-05-27 |
2014-03-15 |
شركة جانسين فارماسوتيكا ان. في |
Quinazoline derivatives
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
TW200510373A
(en)
|
2003-07-14 |
2005-03-16 |
Neurogen Corp |
Substituted quinolin-4-ylamine analogues
|
US7329664B2
(en)
|
2003-07-16 |
2008-02-12 |
Neurogen Corporation |
Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
|
US7501427B2
(en)
|
2003-08-14 |
2009-03-10 |
Array Biopharma, Inc. |
Quinazoline analogs as receptor tyrosine kinase inhibitors
|
PT1660090E
(pt)
|
2003-08-14 |
2013-01-11 |
Array Biopharma Inc |
Análogos de quinazolina como inibidores de tirosina-cinases recetoras
|
BRPI0414489A8
(pt)
|
2003-09-16 |
2019-01-15 |
Astrazeneca Ab |
derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, processo para a preparação de um derivado de quinazolina
|
GB0322409D0
(en)
|
2003-09-25 |
2003-10-29 |
Astrazeneca Ab |
Quinazoline derivatives
|
DK2210607T3
(da)
|
2003-09-26 |
2011-12-12 |
Exelixis Inc |
N-[3-fluor-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid til behandling af kræft
|
EP1669348A4
(fr)
*
|
2003-09-30 |
2009-03-11 |
Eisai R&D Man Co Ltd |
Agent antifongique a compose heterocyclique
|
US7223761B2
(en)
|
2003-10-03 |
2007-05-29 |
Amgen Inc. |
Salts and polymorphs of a potent antidiabetic compound
|
JP4845736B2
(ja)
|
2003-10-14 |
2011-12-28 |
アリゾナ ボード オブ リージェンツ オン ビハーフ ザ ユニバーシティー オブ アリゾナ |
プロテインキナーゼ阻害剤
|
US20090099165A1
(en)
|
2003-10-14 |
2009-04-16 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Protein Kinase Inhibitors
|
EP1683785B1
(fr)
|
2003-11-11 |
2013-10-16 |
Eisai R&D Management Co., Ltd. |
Derive d'uree et son procede de production
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
US20050171172A1
(en)
|
2003-11-13 |
2005-08-04 |
Ambit Biosciences Corporation |
Amide derivatives as PDGFR modulators
|
JP4936897B2
(ja)
|
2003-12-18 |
2012-05-23 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
抗増殖剤としてのピリド−およびピリミドピリミジン誘導体
|
JP4503022B2
(ja)
|
2003-12-23 |
2010-07-14 |
ファイザー・インク |
新規キノリン誘導体
|
EP1713781B1
(fr)
|
2004-02-03 |
2008-11-05 |
AstraZeneca AB |
Derives de quinazoline
|
TW200529846A
(en)
|
2004-02-20 |
2005-09-16 |
Wyeth Corp |
3-quinolinecarbonitrile protein kinase inhibitors
|
EP1755394A4
(fr)
*
|
2004-04-16 |
2009-08-05 |
Smithkline Beecham Corp |
Methode de traitement du cancer
|
WO2005105761A1
(fr)
*
|
2004-04-28 |
2005-11-10 |
Arrow Therapeutics Limited |
Derives de morpholinylanilinoquinazoline utilises en tant qu'agents antiviraux
|
NZ550796A
(en)
|
2004-05-06 |
2010-07-30 |
Warner Lambert Co |
4-phenylamino-quinazolin-6-yl-amides
|
US20070232607A1
(en)
*
|
2004-06-04 |
2007-10-04 |
Bradbury Robert H |
Quinazoline Derivatives as Erbb Receptor Tyrosine kinases
|
WO2006030826A1
(fr)
|
2004-09-17 |
2006-03-23 |
Eisai R & D Management Co., Ltd. |
Composition medicamenteuse
|
AU2005293336B2
(en)
|
2004-10-12 |
2009-05-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
TW200621251A
(en)
|
2004-10-12 |
2006-07-01 |
Neurogen Corp |
Substituted biaryl quinolin-4-ylamine analogues
|
EP1657241A1
(fr)
|
2004-11-03 |
2006-05-17 |
Schering Aktiengesellschaft |
Nouveaux urées d' anthranylamide pyridine ayant une activité inhibitrice de kinase du récepteur de VEGF
|
EP1655295A1
(fr)
|
2004-11-03 |
2006-05-10 |
Schering Aktiengesellschaft |
Anthranilamide pyridinurées comme inhibiteurs de kinase du récepteur VEGF
|
US7906533B2
(en)
|
2004-11-03 |
2011-03-15 |
Bayer Schering Pharma Ag |
Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
|
NI200700147A
(es)
|
2004-12-08 |
2019-05-10 |
Janssen Pharmaceutica Nv |
Derivados de quinazolina inhibidores de cinasas dirigidos a multip
|
US7947676B2
(en)
|
2004-12-14 |
2011-05-24 |
Astrazeneca Ab |
Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents
|
US8258145B2
(en)
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
CA2592900A1
(fr)
|
2005-01-03 |
2006-07-13 |
Myriad Genetics Inc. |
Composes et utilisation therapeutique associee
|
WO2006090163A1
(fr)
|
2005-02-26 |
2006-08-31 |
Astrazeneca Ab |
Dérivés de quinazoline servant d'inhibiteurs de tyrosine kinase
|
ES2351613T3
(es)
*
|
2005-03-03 |
2011-02-08 |
Santen Pharmaceutical Co., Ltd. |
Nuevo compuesto cíclico que tiene un grupo quinolilalquiltio.
|
US7829585B2
(en)
|
2005-03-30 |
2010-11-09 |
Eisai R&D Management Co., Ltd. |
Antifungal agent containing pyridine derivative
|
US7825244B2
(en)
|
2005-06-10 |
2010-11-02 |
Janssen Pharmaceutica Nv |
Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
|
US8071768B2
(en)
|
2005-06-10 |
2011-12-06 |
Janssen Pharmaceutica, N.V. |
Alkylquinoline and alkylquinazoline kinase modulators
|
KR20080030058A
(ko)
|
2005-07-27 |
2008-04-03 |
에프. 호프만-라 로슈 아게 |
5-ht6 조절인자로서 4-아릴옥시 퀴놀린 유도체
|
WO2007015578A1
(fr)
|
2005-08-02 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
Procédé d’analyse de l’effet d’un inhibiteur de vascularisation
|
WO2007034144A1
(fr)
|
2005-09-20 |
2007-03-29 |
Astrazeneca Ab |
Composes de 4- (ih-indazol-s-yl-amino)-quinazoline utilises comme inhibiteurs des tyrosines kinases erbb associees au recepteur pour traiter le cancer
|
GB0520475D0
(en)
*
|
2005-10-07 |
2005-11-16 |
Arrow Therapeutics Ltd |
Chemical compounds
|
TWI385169B
(zh)
|
2005-10-31 |
2013-02-11 |
Eisai R&D Man Co Ltd |
經雜環取代之吡啶衍生物及含有彼之抗真菌劑
|
US8648087B2
(en)
|
2005-11-15 |
2014-02-11 |
Array Biopharma, Inc. |
N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
|
US7960545B2
(en)
|
2005-11-23 |
2011-06-14 |
Natco Pharma Limited |
Process for the prepartion of erlotinib
|
RU2441869C2
(ru)
|
2005-12-21 |
2012-02-10 |
Эбботт Лэборетриз |
Противовирусные соединения
|
ATE475660T1
(de)
|
2005-12-21 |
2010-08-15 |
Abbott Lab |
Antivirale verbindungen
|
EP1971611B1
(fr)
|
2005-12-21 |
2012-10-10 |
Abbott Laboratories |
Composes anti-viraux
|
CN101003514A
(zh)
*
|
2006-01-20 |
2007-07-25 |
上海艾力斯医药科技有限公司 |
喹唑啉衍生物、其制备方法及用途
|
UY30183A1
(es)
|
2006-03-02 |
2007-10-31 |
Astrazeneca Ab |
Derivados de quinolina
|
JPWO2007119361A1
(ja)
|
2006-03-17 |
2009-08-27 |
三菱瓦斯化学株式会社 |
キナゾリン−4−オン誘導体の製造方法
|
AU2007251282A1
(en)
|
2006-05-09 |
2007-11-22 |
Pfizer Products Inc. |
Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
|
CA2652442C
(fr)
|
2006-05-18 |
2014-12-09 |
Eisai R & D Management Co., Ltd. |
Agent antitumoral destine au cancer de la thyroide
|
JP2009542778A
(ja)
|
2006-07-13 |
2009-12-03 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
Mtkiキナゾリン誘導体
|
KR101472600B1
(ko)
|
2006-08-28 |
2014-12-15 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
미분화형 위암에 대한 항종양제
|
WO2008035726A1
(fr)
|
2006-09-21 |
2008-03-27 |
Eisai R & D Management Co., Ltd. |
Dérivé de pyridine substitué par un cycle hétéroaryle, et agent antifongique le comprenant
|
EP1921070A1
(fr)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
heterocycles bicycliques, medicaments á base de ces composes, leur usage et procédé pour leur preparation
|
US8754107B2
(en)
|
2006-11-17 |
2014-06-17 |
Abbvie Inc. |
Aminopyrrolidines as chemokine receptor antagonists
|
US8236950B2
(en)
|
2006-12-20 |
2012-08-07 |
Abbott Laboratories |
Anti-viral compounds
|
EP2119707B1
(fr)
|
2007-01-29 |
2015-01-14 |
Eisai R&D Management Co., Ltd. |
Composition destinée au traitement d'un cancer de l'estomac de type indifférencié
|
CA2677336A1
(fr)
|
2007-02-06 |
2008-08-14 |
Boehringer Ingelheim International Gmbh |
Heterocycles bicycliques, agents pharmaceutiques contenant ces composes, leur utilisation et leur procede de preparation
|
CN101245050A
(zh)
*
|
2007-02-14 |
2008-08-20 |
上海艾力斯医药科技有限公司 |
4-苯胺喹唑啉衍生物的盐
|
DK2146779T3
(en)
|
2007-04-18 |
2016-11-28 |
Pfizer Prod Inc |
Sulfonylamid derivatives to treat abnormal cell growth.
|
CA2685194A1
(fr)
|
2007-04-27 |
2008-11-13 |
Eisai R&D Management Co., Ltd. |
Sel d'un derive de pyridine substitue par heterocycle ou cristaux dudit sel
|
CA2693588C
(fr)
*
|
2007-07-13 |
2015-11-17 |
Icagen, Inc. |
Inhibiteurs des canaux sodiques
|
WO2009016132A1
(fr)
|
2007-07-27 |
2009-02-05 |
Janssen Pharmaceutica Nv |
Pyrrolopyrimidines
|
EP2220054A2
(fr)
|
2007-10-29 |
2010-08-25 |
Natco Pharma Limited |
Nouveaux dérivés de la 4-(tétrazol-5-yl)-quinazoline en tant qu'agents anti-cancéreux
|
US20090291971A1
(en)
*
|
2007-11-01 |
2009-11-26 |
Wyeth |
Heteroaryl ethers and processes for their preparation
|
JP5638244B2
(ja)
|
2007-11-09 |
2014-12-10 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質と抗腫瘍性白金錯体との併用
|
WO2009079797A1
(fr)
|
2007-12-26 |
2009-07-02 |
Critical Outcome Technologies, Inc. |
Composés et procédé pour le traitement du cancer
|
US8513287B2
(en)
|
2007-12-27 |
2013-08-20 |
Eisai R&D Management Co., Ltd. |
Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
|
NZ586582A
(en)
|
2008-02-07 |
2012-07-27 |
Boehringer Ingelheim Int |
Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
|
ES2391373T3
(es)
*
|
2008-04-16 |
2012-11-23 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Derivados de quinoleína como inhibidores de la cinasa AXL
|
WO2009137714A2
(fr)
|
2008-05-07 |
2009-11-12 |
Teva Pharmaceutical Industries Ltd. |
Formes de ditosylate de lapatinib et procédés pour leur préparation
|
ES2444128T3
(es)
|
2008-05-13 |
2014-02-24 |
Astrazeneca Ab |
Nueva SAL-554
|
US8426430B2
(en)
*
|
2008-06-30 |
2013-04-23 |
Hutchison Medipharma Enterprises Limited |
Quinazoline derivatives
|
JP2010018531A
(ja)
*
|
2008-07-09 |
2010-01-28 |
Sumitomo Seika Chem Co Ltd |
3−ベンジルオキシベンゼンチオールの製造方法
|
EP2318406B1
(fr)
|
2008-07-17 |
2016-01-27 |
Critical Outcome Technologies, Inc. |
Composés inhibiteurs et procédés de traitement du cancer
|
JP5539351B2
(ja)
|
2008-08-08 |
2014-07-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
|
EP2241565A1
(fr)
|
2009-01-15 |
2010-10-20 |
Universität Leipzig |
Composés inhibiteurs de l'aurora kinase
|
WO2010083414A1
(fr)
|
2009-01-16 |
2010-07-22 |
Exelixis, Inc. |
Sel de malate de n-(4-{[6,7-bis(méthyloxy)quinolin-4-yl]oxy}phényl)-n'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide et formes cristallines de celui-ci pour le traitement du cancer
|
KR101106050B1
(ko)
|
2009-03-25 |
2012-01-18 |
한국과학기술연구원 |
아미노퀴놀린 화합물, 이의 제조 방법 및 이를 함유하는 의약 조성물
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
CA2772194A1
(fr)
|
2009-09-01 |
2011-03-10 |
Pfizer Inc. |
Derives de benzimidazole
|
DK3575288T3
(da)
|
2009-09-03 |
2021-12-20 |
Bristol Myers Squibb Co |
Quinazoliner som kaliumionkanalinhibitorer
|
CA2784807C
(fr)
*
|
2009-12-29 |
2021-12-14 |
Dana-Farber Cancer Institute, Inc. |
Inhibiteurs de kinase raf de type ii
|
EP2552915B1
(fr)
|
2010-04-01 |
2017-07-19 |
Critical Outcome Technologies Inc. |
Composés pour le traitement du vih
|
JP2013526484A
(ja)
*
|
2010-05-07 |
2013-06-24 |
グラクソ グループ リミテッド |
キナーゼ阻害剤としてのアミノ‐キノリン
|
KR101677790B1
(ko)
|
2010-06-25 |
2016-11-18 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
키나제 저해 작용을 갖는 화합물의 병용에 의한 항종양제
|
ES2543151T3
(es)
|
2010-10-20 |
2015-08-17 |
Pfizer Inc |
Derivados de 2-piridina como moduladores del receptor Smoothened
|
KR101940340B1
(ko)
|
2011-03-04 |
2019-01-18 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
키나제 억제제로서의 아미노-퀴놀린
|
AU2012246490B2
(en)
|
2011-04-18 |
2016-08-04 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
WO2012166899A2
(fr)
|
2011-06-03 |
2012-12-06 |
Eisai R&D Management Co., Ltd. |
Biomarqueurs pour la prédiction et l'estimation de la sensibilité de sujets atteints d'un cancer de la thyroïde et du rein vis-à-vis de composés lenvatinib
|
CN102850280B
(zh)
*
|
2011-06-30 |
2015-06-10 |
陕西师范大学 |
6,7-二烷氧基-4-取代苯基氨基喹唑啉类化合物及其制备方法
|
WO2013013614A1
(fr)
*
|
2011-07-28 |
2013-01-31 |
南京英派药业有限公司 |
4-(3-hétéroarylarylamino)quinazoline et 1-(3-hétéroarylarylamino)isoquinoline utilisées en tant qu'inhibiteurs de la voie hedgehog et leur utilisation
|
TWI547494B
(zh)
|
2011-08-18 |
2016-09-01 |
葛蘭素史克智慧財產發展有限公司 |
作為激酶抑制劑之胺基喹唑啉類
|
AU2012311184A1
(en)
|
2011-09-22 |
2014-03-06 |
Pfizer Inc. |
Pyrrolopyrimidine and purine derivatives
|
TW201425307A
(zh)
|
2012-09-13 |
2014-07-01 |
Glaxosmithkline Llc |
作為激酶抑制劑之胺基-喹啉類
|
AR092529A1
(es)
|
2012-09-13 |
2015-04-22 |
Glaxosmithkline Llc |
Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
|
MX2015004979A
(es)
|
2012-12-21 |
2015-07-17 |
Eisai R&D Man Co Ltd |
Forma amorfa de derivado de quinolina y metodo para su produccion.
|
BR112015018282B1
(pt)
*
|
2013-02-01 |
2021-08-24 |
Wellstat Therapeutics Corporation |
Compostos de amina, composição compreendendo os referidos compostos e usos dos mesmos
|
KR20150118152A
(ko)
|
2013-02-21 |
2015-10-21 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
키나제 억제제로서의 퀴나졸린
|
RU2658601C2
(ru)
|
2013-05-14 |
2018-06-21 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Биомаркер для прогнозирования и оценки чувствительности субъектов с раком эндометрия к соединениям ленватиниба
|
MY191804A
(en)
|
2013-09-16 |
2022-07-15 |
Astrazeneca Ab |
Therapeutic polymeric nanoparticles and methods of making and using same
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
WO2015155624A1
(fr)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dérivés de dihydropyrrolopyrimidine
|
US20170050958A1
(en)
|
2014-04-30 |
2017-02-23 |
Pfizer Inc. |
Cycloalkyl-Linked Diheterocycle Derivatives
|
WO2016001789A1
(fr)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Dérivés de pyrimidine en tant qu'inhibiteurs de pi3k destinés à être utilisés dans le traitement du cancer
|
EP4089076A1
(fr)
|
2014-08-28 |
2022-11-16 |
Eisai R&D Management Co., Ltd. |
Dérivé de quinoline à pureté élevée et son procédé de fabrication
|
RS65049B1
(sr)
|
2015-02-25 |
2024-02-29 |
Eisai R&D Man Co Ltd |
Metoda za suzbijanje gorčine derivata kinolina
|
CA2978226A1
(fr)
|
2015-03-04 |
2016-09-09 |
Merck Sharpe & Dohme Corp. |
Association d'un antagoniste de pd-1 et d'un inhibiteur des tyrosines kinases vegfr/fgfr/ret pour traiter le cancer
|
US10548897B2
(en)
|
2015-04-16 |
2020-02-04 |
Icahn School Of Medicine At Mount Sinai |
KSR antagonists
|
ES2886107T3
(es)
|
2015-06-16 |
2021-12-16 |
Prism Biolab Co Ltd |
Antineoplásico
|
WO2017009751A1
(fr)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Dérivés de pyrimidine
|
BR112018006873A2
(pt)
|
2015-10-05 |
2018-11-06 |
The Trustees Of Columbia University In The City Of New York |
ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias
|
CN105384699B
(zh)
|
2015-10-23 |
2016-10-12 |
中国人民解放军南京军区南京总医院 |
一种新型喹唑啉衍生物lu1501及其制备方法和应用
|
CN105503747B
(zh)
*
|
2015-12-03 |
2017-12-19 |
中国人民解放军南京军区南京总医院 |
一种喹唑啉衍生物lu1507及其制备方法和应用
|
CN105669567A
(zh)
*
|
2015-12-28 |
2016-06-15 |
上海应用技术学院 |
一种酪氨酸激酶抑制剂及其制备方法和用途
|
US11053223B2
(en)
*
|
2017-04-27 |
2021-07-06 |
Astrazeneca Ab |
Phenoxyquinazoline compounds and their use in treating cancer
|
MX2019012847A
(es)
|
2017-04-27 |
2022-01-07 |
Astrazeneca Ab |
Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
|
US20200290978A1
(en)
*
|
2017-09-26 |
2020-09-17 |
The Regents Of The University Of California |
Compositions and methods for treating cancer
|
CN108373452B
(zh)
*
|
2018-02-09 |
2020-10-27 |
安庆奇创药业有限公司 |
一种拉帕替尼关键中间体的制备方法
|
CN111303024B
(zh)
*
|
2018-12-12 |
2023-03-28 |
安徽中科拓苒药物科学研究有限公司 |
一种喹啉结构的pan-KIT激酶抑制剂及其用途
|
CN112778217B
(zh)
*
|
2019-11-08 |
2024-01-26 |
沈阳化工研究院有限公司 |
一种喹唑啉类化合物及其应用
|
WO2022258057A1
(fr)
*
|
2021-06-11 |
2022-12-15 |
Jingrui Biopharma Co., Ltd. |
Composés en tant qu'agents anticancéreux
|
CN114436975B
(zh)
*
|
2022-01-26 |
2023-10-31 |
贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) |
2-三氟甲基-4-氨基喹唑啉类化合物及其应用
|